FDA Says to Drop Suicide Warning From GLP-1 Drug Labels

(MedPage Today) — The FDA requested that manufacturers of GLP-1 receptor agonists remove information regarding risks of suicidal behavior and ideation from drug labels following a detailed review of existing data, the agency announced on Tuesday…

Source link : https://www.medpagetoday.com/primarycare/obesity/119405

Author :

Publish date : 2026-01-13 20:43:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

FDA Says to Drop Suicide Warning From GLP-1 Drug Labels

Slow Heart Rate May Signal Xylazine Involvement in Opioid Overdoses

Rare Childhood Disorder Gets Its First FDA Drug Approval

Related Posts

ChatGPT Excels at Classifying Ultraprocessed Foods

Pregnancy Hypertension Timing Tied to Long-term Hypertension

Long-Acting HIV Drug Switch Shows No Major Metabolic Impact

Rapamycin can add years to your life, or none at all – it’s a lottery

Parental Obesity Before Pregnancy Linked to Kids’ Chronic Liver Disease Risk

States Sue Trump Admin Over Changes to Childhood Vaccine Recommendations

ChatGPT Excels at Classifying Ultraprocessed Foods

Pregnancy Hypertension Timing Tied to Long-term Hypertension

Long-Acting HIV Drug Switch Shows No Major Metabolic Impact

Rapamycin can add years to your life, or none at all – it’s a lottery

Parental Obesity Before Pregnancy Linked to Kids’ Chronic Liver Disease Risk

States Sue Trump Admin Over Changes to Childhood Vaccine Recommendations

FDA Approves a Balloon That Patients Swallow to Lose Weight

More Residency Slots Needed in Rural Areas, Lawmakers and Health Experts Say

Categories

Archives